Skip to main content

Table 1 Sample demographics for association analyses with Alzheimer’s disease case-control status

From: Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping

Cohort

APOE*3/4 carriers

APOE*4/4 carriers

Name

Participants after QC (N)

Diagnosis (N)

(N (%))

Female (N (%))

Age (Mean (SD))

(N (%))

Female (N (%))

Age (Mean (SD))

Discovery

25120

CN

12340

2707 (21.9 %)

1615 (59.7 %)

76.2 (8.4)

238 (1.9 %)

145 (60.9 %)

73.7 (7.4)

AD

12780

5740 (44.9 %)

3411 (59.4 %)

73.8 (6.9)

1652 (12.9 %)

895 (54.2 %)

70.1 (6.2)

Replication - Rotterdam

10150

CN

8824

1868 (21.2 %)

1034 (55.4 %)

76.4 (9.3)

150 (1.7 %)

74 (49.3 %)

73.8 (8.0)

AD

1326

411 (31.0 %)

282 (68.6 %)

82.2 (6.4)

86 (6.5 %)

50 (58.1 %)

78.2 (6.9)

Replication - EADI

8571

CN

6502

1141 (17.5 %)

672 (58.9 %)

79.6 (6.4)

62 (1.0 %)

45 (72.6 %)

77.8 (6.4)

AD

2069

801 (38.7 %)

529 (66.0 %)

73.9 (7.4)

205 (9.9 %)

134 (65.4 %)

69.4 (5.9)

Replication - EADB

21860

CN

12295

2498 (20.3 %)

1431 (57.3 %)

72.4 (7.9)

195 (1.6 %)

107 (54.9 %)

70.3 (7.5)

AD

9565

3912 (40.9 %)

2522 (64.5 %)

74.0 (7.2)

959 (10.0 %)

551 (57.5 %)

70.4 (6.8)

  1. Cohort data were available through the National Institute on Aging and Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS), the National Alzheimer’s Coordinating Center (NACC), Accelerating Medicines Partnership – Alzheimer’s Disease (AMP-AD) Knowledge Portal, the Database of Genotypes and Phenotypes (dbGaP), Rush Alzheimer’s Disease Center at Rush University, the Image & Data Archive powered by Laboratory of Neuro Imaging (IDA-LONI), the Rotterdam study, the European Alzheimer’s Disease Initiative (EADI), and the European Alzheimer & Dementia BioBank (EADB). Cohorts included Adult Changes in Thought (ACT), Alzheimer’s Disease Center Datasets (ADC1-7) for which phenotype data is managed by NACC, European collaboration for the discovery of novel biomarkers for Alzheimer’s disease (ADDNEURO), the Alzheimer’s Disease Neuroimaging Initiative (ADNI), ADNI Department of Defense (ADOD), Alzheimer’s Disease Sequencing Project (ADSP) Discovery and Extension Phase, National Institute on Aging Genetics Initiative for Late-Onset Alzheimer’s Disease (NIA-LOAD), Oregon Health and Science University study (OHSU), Mayo Clinic Alzheimer’s Disease Genetics studies (MAYO), MAYO RNAseq study (MAYO2), Multi Institutional Research on Alzheimer Genetics Epidemiology (MIRAGE), Mount Sinai Brain Bank (MSBB), University of Miami/Texas Alzheimer’s Research Care Consortium Wave 2/Case Western Reserve University (MTC), Rush University Religious Orders Study/Memory and Aging Project (ROSMAP), Translational Genomics Research Institute series 2 (TGEN2), University of Miami/Vanderbilt University/Mt. Sinai School of Medicine studies (UM/VU/MSSM), University of Pittsburgh study (UPITT), the Washington University study (WASHU), Washington Heights-Inwood Community Aging Project (WHICAP), the Rotterdam study, the European Alzheimer’s Disease Initiative (EADI), and the European Alzheimer & Dementia BioBank (EADB)
  2. Abbreviations: CN cognitively normal, AD Alzheimer’s disease, QC quality control, SD standard deviation, SNP single nucleotide polymorphism
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193